Amgen will pay $4 billion to acquire ChemoCentryx, adding a recently approved medicine for an autoimmune condition.
Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology business that specialises in creating targeted and immuno-oncology cancer treatments, today announced a deal under which Amgen will buy Five Prime Therapeutics for $38 per share in cash, or roughly $1.9 billion in equity. Amgen’s premier cancer portfolio now includes Five Prime’s cutting-edge pipeline as a result of this purchase. READ MORE